Ishay Attar, MBA, MSc
Ishay Attar, MBA, MSc is the Founder, Chairman, and CTO of BioChange, a regenerative medicine company pioneering CellFoam™, a bioabsorbable foam scaffold that promotes tissue regeneration by restoring cell communication in a manner resembling embryonic tissue behavior.
Ishay is a healthcare innovator and serial entrepreneur with three degrees from the Technion – Israel Institute of Technology, and is credited as the founder of four healthcare startups, two of which — LifeBond and OutSense — have been acquired by large American corporations.
Since founding BioChange in 2017, Ishay has built the company around the proprietary CellFoam™ platform, a protein-based 3D foam scaffold developed to stimulate tissue regeneration in indications spanning periodontal disease, urology, aesthetic dermatology, and hemostasis. The company’s flagship product, ReGum, addresses periodontal tissue loss — an unmet medical need affecting approximately 40% of adults over 30. In a peer-reviewed clinical study published in Frontiers in Veterinary Science, ReGum was found to be safe and superior to standard periodontal therapy alone in regenerating periodontal tissue in dogs.
Read Treatment of Naturally Occurring Periodontitis in Dogs With a New Bio-Absorbable Regenerative Matrix.
A veterinary version of ReGum launched commercially in 2023 and is now distributed across Europe, South Korea, and the United States, with PRN Pharmacal introducing ReGum Vet to US veterinarians in 2025. BioChange anticipates FDA clearance of ReGum for human use by 2026. Read BioChange’s ReGum has been scientifically proven to heal gum recession disease, ReGum from BioChange Scientifically Proven to Heal Gum Recession Disease. and Medical device for periodontal tissue repair launches in US market.
BioChange has extended the CellFoam platform into adjacent product lines, including Revolette, a next-generation aesthetic biostimulator, and vitaloc, a hemostatic powder for veterinary surgery.
Before BioChange, Ishay founded and served as Chairman of OutSense, an Israeli startup he established in 2016 to develop an IoT toilet-mounted sensor capable of analyzing stool and urine for early detection of colorectal cancer, dehydration, urinary tract infections, and other gastrointestinal and systemic conditions. OutSense was acquired by Kohler, and its technology now underpins Dekoda, the flagship product of Kohler’s new Kohler Health division launched in 2025. Read Kohler’s Dekoda is $600 camera for your toilet and An IoMT Device That Can Detect Disease Through the Toilet Bowl.
Earlier in his career, between 2007 and 2020, Ishay founded and led LifeBond. as CEO and Founder, a biomaterials surgery company based in Caesarea, Israel, developing surgical sealants, mesh adhesives, and severe-bleeding hemostatic dressings. LifeBond raised approximately $60 million from investors including Pitango, Aurum Ventures, Adams Street Partners, Sino Biopharmaceutical, Glenrock, Giza, and Johnson & Johnson, and was acquired in January 2020 by Bard, a division of Becton, Dickinson and Company (BD). Read Bard buys Israeli hernia mesh co LifeBond.
Ishay remains actively engaged in several additional ventures. Since 2014, he has been Cofounder of Eximore, a Jerusalem-based ophthalmic drug-delivery company developing a non-invasive punctal plug that releases glaucoma medication over a controlled period, addressing the chronic compliance problem associated with daily eye drops. The next product in Eximore’s pipeline targets dry eye syndrome. Also since 2014, he has been Cofounder of B.G. Guard, an Israeli startup developing a novel therapy for diabetes.
Since August 2022, Ishay has been an investor in Tarsier Pharma, a late clinical-stage ophthalmic biopharmaceutical company developing dazdotuftide (TRS01), a first-in-class steroid-free therapy for non-infectious uveitis and uveitic glaucoma, which received FDA agreement under a Special Protocol Assessment for its Tarsier-04 Phase 3 trial. Read Tarsier Pharma Receives FDA Agreement Under Special Protocol Assessment (SPA) for Tarsier-04 Phase 3 Trial of TRS01.
Between 2013 and 2018, Ishay served as CEO of Respinova, where he led clinical development of the PulseHaler™, a non-invasive device that administers multi-frequency positive-pressure air pulsations to reopen collapsed small airways in patients with chronic obstructive pulmonary disease (COPD) — an unmet need affecting 5–10% of the population. The technology was clinically validated at Hadassah Medical Center and Yitzhak Shamir Medical Center and supported by the European Union’s Horizon 2020 SME Instrument programme.
Read Randomized controlled crossover trial of a new oscillatory device as add-on therapy for COPD and Pressure pulsations enhance penetration index in COPD. and COPD innovation may keep Covid patients off ventilators.
Between 2006 and 2020, Ishay was a Cofounder of NeuroQuest, and from 2014 to 2016 he served as a Director of Tefenplastic. Ishay began his career in Israeli healthcare innovation at Trendlines Medical, where he was VP Business Development from 2003 to 2007. Trendlines is one of Israel’s leading medical-technology incubators, funded by the Trendlines Israel Fund and supported by the Israeli Office of the Chief Scientist. During his tenure, he managed deal flow and screening for new investments, linking entrepreneurs with technology, service providers, and investors, and recruited and fostered the growth of 16 early-stage companies.
Thanks to the success of the majority of those companies, the Misgav incubator became the leading incubator in the country and in 2009 was named “Best Incubator” by the Office of the Chief Scientist of Israel. Read Under the radar tech incubator named best in Israel.
Ishay earned his MBA. in Entrepreneurship and Management from the Technion – Israel Institute of Technology in 2006, with a concentration in biomedical studies. He earned his MSc in Biomedical Engineering from the Technion Faculty of Biomedical Engineering in 2003 and his BSc in Biotechnology Engineering from the Technion Faculty of Biotechnology and Food Engineering in 1999.
He has been recognized as one of the 100 most influential Technion graduates of all time. Ishay’s current work sits at the intersection of tissue engineering, regenerative medicine, and healthy longevity science. He is a confirmed speaker at Longevity Nation 2026, the international healthy-longevity conference hosted at Bar-Ilan University, where he will present The embryonic FOAM of life, regenerating aged and damaged tissues.
Read his speaker profile at Longevity Nation. Ishay lives in Nachsholim in the Haifa District of Israel.
Visit his LinkedIn profile and the BioChange homepage. Follow him on Facebook, Instagram, and X.